All In Biotech

Drug Trial Radar · NCT07707895

DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

A Phase Ib/II, Open-label, Safety and Tolerability Trial of Obrixtamig in Combination With ZL-1310 in Patients With Poorly Differentiated NEC

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Nov 3, 2026

Primary completion

Apr 26, 2030

Study completion Apr 26, 2030

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
Collaborators
Zai Lab
First posted
Jul 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with advanced small cell lung cancer and other neuroendocrine cancers. The study has 2 parts. The purpose of Part 1 is to find a suitable dose of a combination study treatment, obrixtamig and ZL-1310. The purpose of Part 2 is to see how obrixtamig and ZL-1310 is tolerated when given with another medicine called a checkpoint inhibitor. Another purpose is to check whether the study treatment can stop the cancer from growing and keep it stable. Obrixtamig and ZL-1310 are being developed to help the immune system fight cancer. In Part 1, participants get obrixtamig and ZL-1310. In Part 2, participants get obrixtamig and ZL-1310 with a checkpoint inhibitor. Part 2 is only open to people with advanced small cell lung cancer. All study treatments are given as infusions into a vein. The study does not have a fixed duration. Participants can receive study treatment for up to 2 years if they benefit from treatment and can tolerate it. Participants visit the study site regularly, with some overnight stays required. During this time, doctors regularly check for health problems that could be caused by the study treatment. They also monitor the size of the tumour(s) and take laboratory tests.

Conditions

  • Small Cell Lung Cancer
  • Large Cell Neuroendocrine Lung Carcinoma
  • Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology
  • Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology

Interventions

  • ObrixtamigDrug

    Obrixtamig

  • ZL-1310Drug

    ZL-1310

  • AtezolizumabDrug

    Atezolizumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: The occurrence of dose limiting toxicities (DLTs) during the DLT evaluation periodTime frame: 6 weeks from the first administration of study medication.
  2. Part 2: The occurrence of treatment-emergent adverse events (AEs) leading to trial medication discontinuation or dose modificationTime frame: Up to 24 months.
  3. Part 2: PFS rate at 6 monthsTime frame: At 6 months.

Locations

28 sites in 11 countries. Site status is shown where the registry gives one.

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia · Not yet recruiting

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida · Not yet recruiting

  • University of Kentucky Medical Center

    Lexington, Kentucky · Recruiting

  • Chris Obrien Lifehouse

    Camperdown, New South Wales, Australia · Not yet recruiting

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia · Not yet recruiting

  • Universitair Ziekenhuis Antwerpen

    Edegem, Belgium · Not yet recruiting

  • Universitair Ziekenhuis Gent

    Ghent, Belgium · Not yet recruiting

  • The Affiliated Cancer Hospital, Guangxi Medical University

    Nanning, China · Not yet recruiting

  • Shanghai Chest Hospital

    Shanghai, China · Not yet recruiting

  • Shanghai Pulmonary Hospital

    Shanghai, China · Not yet recruiting

  • CTR Leon Berard

    Lyon, France · Not yet recruiting

  • HOP Timone

    Marseille, France · Not yet recruiting

  • Institut Gustave Roussy

    Villejuif, France · Not yet recruiting

  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz

    Mainz, Germany · Not yet recruiting

  • Robert Bosch Gesellschaft für medizinische Forschung mbH

    Stuttgart, Germany · Recruiting

  • Hokkaido Cancer Center

    Hokkaido, Sapporo, Japan · Not yet recruiting

  • St. Marianna University Hospital

    Kanagawa, Kawasaki, Japan · Not yet recruiting

  • Kansai Medical University Hospital

    Osaka, Hirakata, Japan · Not yet recruiting

  • Shizuoka Cancer Center

    Shizuoka, Sunto-gun, Japan · Not yet recruiting

  • Amsterdam UMC Locatie VUMC

    Amsterdam, Netherlands · Not yet recruiting

  • Szpital Specjalistyczny W Brzozowie Podkarpacki Osrodek Onkologiczny Im.Ks.B.Markiewicza

    Brzozów, Poland · Not yet recruiting

  • Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy

    Warsaw, Poland · Not yet recruiting

  • Lower Silesian Oncology Centre

    Wroclaw, Poland · Not yet recruiting

  • Hospital Duran i Reynals

    L'Hospitalet Del Llobregat, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Hospital Clinico De Valencia (INCLIVA)

    Valencia, Spain · Recruiting

  • Leicester Royal Infirmary

    Leicester, United Kingdom · Not yet recruiting

  • Freeman Hospital

    Newcastle upon Tyne, United Kingdom · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.